[{"address1": "3480 Peachtree Road NE", "address2": "Second Floor, Suite 103", "city": "Atlanta", "state": "GA", "zip": "30326", "country": "United States", "phone": "844 722 6333", "website": "https://www.alzamend.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.", "fullTimeEmployees": 4, "companyOfficers": [{"maxAge": 1, "name": "Mr. Stephan  Jackman", "age": 47, "title": "CEO & Director", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 443617, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Milton Charles Ault III", "age": 53, "title": "Founder & Vice Chairman", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 8333, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David J. Katzoff", "age": 61, "title": "Chief Financial Officer", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 150000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Henry C. W. Nisser Esq.", "age": 54, "title": "Executive VP, General Counsel & Director", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 50000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kenneth S. Cragun CPA", "age": 62, "title": "Senior Vice President of Finance", "yearBorn": 1961, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 25000}], "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 4, "previousClose": 2.42, "open": 2.4, "dayLow": 2.1303, "dayHigh": 2.4699, "regularMarketPreviousClose": 2.42, "regularMarketOpen": 2.4, "regularMarketDayLow": 2.1303, "regularMarketDayHigh": 2.4699, "beta": -0.008, "forwardPE": -0.1938053, "volume": 462069, "regularMarketVolume": 462069, "averageVolume": 1615544, "averageVolume10days": 1174510, "averageDailyVolume10Day": 1174510, "marketCap": 1842315, "fiftyTwoWeekLow": 1.835, "fiftyTwoWeekHigh": 42.0, "fiftyDayAverage": 3.37168, "twoHundredDayAverage": 7.26392, "currency": "USD", "enterpriseValue": 1960466, "floatShares": 715197, "sharesOutstanding": 841240, "sharesShort": 25874, "sharesShortPriorMonth": 7613, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0308, "heldPercentInsiders": 0.24222, "heldPercentInstitutions": 0.04519, "shortRatio": 0.49, "shortPercentOfFloat": 0.040599998, "impliedSharesOutstanding": 841240, "bookValue": -3.771, "lastFiscalYearEnd": 1714435200, "nextFiscalYearEnd": 1745971200, "mostRecentQuarter": 1714435200, "netIncomeToCommon": -9947746, "trailingEps": -147.0, "forwardEps": -11.3, "lastSplitFactor": "1:10", "lastSplitDate": 1721088000, "enterpriseToEbitda": -0.198, "52WeekChange": -0.94024694, "SandP52WeekChange": 0.24014747, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "ALZN", "underlyingSymbol": "ALZN", "shortName": "Alzamend Neuro, Inc.", "longName": "Alzamend Neuro, Inc.", "firstTradeDateEpochUtc": 1623763800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "b0577044-824a-3769-9c91-1a7bb4b1f2b7", "messageBoardId": "finmb_367712111", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.19, "targetHighPrice": 50.0, "targetLowPrice": 50.0, "targetMeanPrice": 50.0, "targetMedianPrice": 50.0, "recommendationMean": 2.5, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 376048, "totalCashPerShare": 0.447, "ebitda": -9886905, "totalDebt": 300714, "quickRatio": 0.117, "currentRatio": 0.141, "returnOnAssets": -1.8973, "returnOnEquity": -44.08309, "freeCashflow": -4687545, "operatingCashflow": -8269993, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]